Lila Biologics, Inc.
Lila Bio is a therapeutic biotechnology company that applies machine learning and high-throughput experimental platforms to design and develop protein therapeutics. The company's stated focus areas include targeted radioligand therapies for solid tumors and long-acting injectable protein therapeutics for non-oncology indications. Their approach combines computational protein design, experimental optimization for affinity and selectivity, chemistry for conjugation and synthesis, and formulation/developability work aimed at subcutaneous delivery and tailored pharmacokinetics.
Industries
N/A
Nr. of Employees
small (1-50)
Lila Biologics, Inc.
Services
End-to-end discovery workflows that combine computational design and experimental optimization to produce development candidates for oncology and non-oncology indications.
End-to-end discovery workflows that combine computational design and experimental optimization to produce development candidates for oncology and non-oncology indications.
Expertise Areas
- AI-enabled protein design
- Protein engineering and de novo binder design
- Radioligand/targeted radiotherapy development
- Long-acting injectable therapeutics
Key Technologies
- AI-driven protein design
- De novo protein design
- Computational protein modeling (diffusion-based methods)
- Unnatural/noncanonical amino acid incorporation
News & Updates
News coverage reporting a collaboration with Eli Lilly focused on cancer and AI-enabled therapeutic discovery (solid tumors / radioligand therapies).
Industry press coverage on company formation and a collaboration with Lilly for radioligand therapy discovery and development.
Press release announcing a collaboration focused on radioligand therapy discovery and development.
Publication describing de novo designed proteins that modulate integrin activity (listed on company media page).
Publication on methods for one-shot design of functional protein binders (listed on company media page).
News item referenced on the media page noting the Nobel Prize award to a scientific founder associated with the lab the company spun out from.
News coverage reporting a collaboration with Eli Lilly focused on cancer and AI-enabled therapeutic discovery (solid tumors / radioligand therapies).
Industry press coverage on company formation and a collaboration with Lilly for radioligand therapy discovery and development.
Press release announcing a collaboration focused on radioligand therapy discovery and development.
Publication describing de novo designed proteins that modulate integrin activity (listed on company media page).
Publication on methods for one-shot design of functional protein binders (listed on company media page).
News item referenced on the media page noting the Nobel Prize award to a scientific founder associated with the lab the company spun out from.